A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ruxolitinib|DRUG: Capecitabine|DRUG: Placebo
Sponsor: Incyte Corporation